Bernstein simply threw contemporary gasoline on Eli Lilly’s (LLY) endless rally, because the agency lifted its value goal on the inventory to $1,300 from $1,100.
For perspective, that’s an 18% bump in comparison with the outdated goal, whereas representing a 21% to 22% upside in comparison with Lilly’s present inventory value.
Analyst Courtney Breen feels Wall Road nonetheless is not factoring in how huge the corporate’s subsequent wave of GLP-1 catalysts may very well be.
She feels Lilly’s unimaginable leap into the trillion-dollar membership, as reported by Reuters, wasn’t the highest, and that 2026 may very well be the turning level the place its illustrious story transitions into real “beat-and-raise” momentum.
Additionally, orforglipron’s approaching launch, White Home coverage is shifting in direction of broader protection, whereas tirzepatide has advanced into turning into a multi-indication platform.
Therefore, Breen sees a setup providing a ton of upside.
Furthermore, it’s necessary to notice that per Tipranks, Breen carries a standout 94% success charge, with 32 of her 34 inventory calls turning a revenue.
On prime of that, her suggestions ship a robust +21.5% common return per score, positioning her among the many prime tier of Wall Road analysts.
Bernstein’s Courtney Breen lifted Eli Lilly’s value goal considerably, citing stronger GLP-1 catalysts forward.
Picture by NurPhoto on Getty Photos
Bernstein thinks Lilly’s run isn’t near performed
Bernstein analyst Breen’s bullishness on Eli Lilly primarily rests on what she dubs as an “incredibly rich” catalyst path that stretches greater than two years.
Most of it’s right down to how a lot earnings energy Mr. Market hasn’t modeled into the inventory.
On the heart of it’s Lilly’s oral GLP-1 orforglipron, which Breen feels will gasoline the following leg of enlargement for the corporate.
Extra Medicare/Medicaid
- What Medicare Half B value hike means in your 2026 Social Safety
- Dave Ramsey sounds nationwide Medicare alarm
- Medicare drug choice can have main impression on older ladies
- Mark Cuban sends sturdy message on main Medicare change
That’s partially as a consequence of a conducive U.S. coverage backdrop that has shifted beneath President Donald Trump’s GLP-1 deal, together with rising world reimbursement channels.
Breen and her crew developed a monetary mannequin slicing Medicare, Medicaid, business, and cash-pay demand on a quarterly schedule operating by means of 2027 and yearly to 2030.
The outcomes confirmed that consensus was nonetheless too conservative on volumes and potential gross sales.
Associated: Cathie Wooden buys the dip in Nvidia-backed inventory
The large breakthrough is predicted to be in 2026.
That’s when orforglipron strikes from promise to revenue engine, with estimated gross sales at an excellent $1.8 billion, which is greater than 3 instances the Road’s view of $550 million.
What’s much more spectacular is that Breen stresses that these lofty numbers are U.S.-only assumptions primarily based on practically 80,000 weekly scripts within the oral weight problems market.
The GLP-1 weight-loss drug market has exploded
Weight-loss medication have successfully been the inventory market’s new rocket gasoline of late, and it appears the trajectory isn’t slowing down any time quickly.
The science behind the GLP-1 (i.e, weight reduction medication) growth is straightforward.
These medication principally flip down the amount knob on starvation whereas including pace bumps to your abdomen.
These medicines mimic the intestine hormones launched after we eat, telling our brains we’re full rather a lot faster whereas slowing down gastric emptying and bettering insulin launch within the course of.
The result’s that we get fewer cravings, together with regular weight reduction over time.
Associated: Goldman Sachs, JPMorgan and BofA drop verdicts on Nvidia earnings
Furthermore, estimates counsel that we’re simply getting began on this development journey.
As an example, Morgan Stanley estimates branded weight problems medication generated a whopping $6 billion in 2023 and practically $15 billion in 2024, in accordance with Morgan Stanley. Additionally, it forecasts the worldwide market to achieve $105 billion by 2030 and probably $150 billion at peak round 2035.
Equally, JPMorgan sees GLP-1s for diabetes and weight problems collectively contributing $100 billion by 2030.
Key gamers and flagship medication within the weight-loss area
- Injectables
Eli Lilly – Mounjaro (tirzepatide) for kind 2 diabetes and Zepbound for weight problems and obstructive sleep apnea (OSA).Novo Nordisk – Ozempic (semaglutide) for diabetes and Wegovy for weight problems; helped push Novo’s obesity-care gross sales alone to DKK 65.1 billion ($9.5 billion) in 2024.
- Capsules (in market or late-stage pipeline)
Novo Nordisk – oral semaglutide (Rybelsus/high-dose 50 mg): Within the OASIS-1 trial, 50 mg once-daily oral semaglutide resulted in practically a 15% common weight reduction (17% in adherent sufferers).Eli Lilly – orforglipron: A once-daily small-molecule GLP-1 tablet; Part 3 knowledge present round 9 to 10% common weight reduction over 72 weeks versus 2 to three% with placebo.
Lilly’s GLP-1 flywheel minted a $1 trillion large
Lilly constructed its approach as much as the trillion-dollar membership, reaching the feat on November 21, spearheaded by its sturdy GLP-1 engine.
The corporate’s weight-loss breakthrough has successfully grow to be a full-blown metabolic-health franchise, led by tirzepatide’s dominance, together with a string of medical wins.
The numbers clarify why traders purchased into its story, with hovering gross sales, tech-style margins, and a pipeline that continues rising its addressable market.
Now with an oral GLP-1 on deck, the flywheel that simply pushed Lilly to $1 trillion continues to be accelerating.
- Document-smashing GLP-1 gross sales: In Q3 2025, BioPharma Dive reported tirzepatide merchandise posted $10 billion+, together with $6.5 billion from Mounjaro (+109% yr over yr) and $3.6 billion from Zepbound (+185% YoY), lifting whole gross sales 54% yr over yr to $17.6 billion.
- A pipeline that stored enlarging the market:In keeping with JAMA Community, Zepbound’s OSA approval (sleep apnea) fashioned a model new reimbursable class, whereas tapping a inhabitants estimated close to 1 billion individuals globally.
- Tech-style profitability: EPS hit $7.02, margins moved into the mid-80s, whereas its valuation jumped practically 200% prior to now three years.
- Subsequent-gen enlargement: Orforglipron’s sturdy Part 3 knowledge positions Lilly to dominate each the injectable and oral GLP-1 markets heading into 2030.
Associated: Tesla will get eye-popping message from newest survey
